- We showed as the first that early intervention in bipolar disorder improves long-term outcome with decreased risk of psychiatric hospitalization and improved adherence to medication and satisfaction with care.
- We demonstrated in two randomised, placebo-controlled phase II trials that 8 weeks of EPO treatment has mood-independent and enduring beneficial effects on cognition across depression and bipolar disorder.
- Our group conducted the first randomized, controlled trial of the effects of 12-weeks group-based cognitive remediation treatment on cognitive function in bipolar disorder. The study revealed no beneficial effects on objectively-measured cognitive function (primary trial outcome), although patients reported some improvement in subjective mental sharpness and quality of life.
Der er ikke registreret en emailaddresse for brugeren/gruppen
Publiceringsdato: 05-10-2016 13:21